Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Afatinib and Necitumumab in Treating Patients with EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Multiple Cancer Types

This phase I trial studies the side effects and best dose of afatinib and necitumumab and to see how well they work in treating patients with EGFR mutation positive non-small cell lung cancer that has spread to other places in the body. Afatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as necitumumab, may interfere with the ability of tumor cells to grow and spread. Giving afatinib and necitumumab may work better in treating patients with EGFR mutation positive non-small cell lung cancer.
Lung, Non Small Cell
I
Horn, Leora
NCT03054038
VICCTHO1684

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: